Health and economic impact of PHiD-CV in Canada and the UK: a Markov modelling exercise.
OBJECTIVE
The spectrum of diseases caused by Streptococcus pneumoniae and non-typeable Haemophilus influenzae (NTHi) represents a large burden on healthcare systems around the world. Meningitis, bacteraemia, community-acquired pneumonia (CAP), and acute otitis media (AOM) are vaccine-preventable infectious diseases that can have severe consequences. The health economic model presented here is intended to estimate the clinical and economic impact of vaccinating birth cohorts in Canada and the UK with the 10-valent, pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV) compared with the newly licensed 13-valent pneumococcal conjugate vaccine (PCV-13).


METHODS
The model described herein is a Markov cohort model built to simulate the epidemiological burden of pneumococcal- and NTHi-related diseases within birth cohorts in the UK and Canada. Base-case assumptions include estimates of vaccine efficacy and NTHi infection rates that are based on published literature.


RESULTS
The model predicts that the two vaccines will provide a broadly similar impact on all-cause invasive disease and CAP under base-case assumptions. However, PHiD-CV is expected to provide a substantially greater reduction in AOM compared with PCV-13, offering additional savings of Canadian $9.0 million and £4.9 million in discounted direct medical costs in Canada and the UK, respectively.


CONCLUSIONS
The main limitations of the study are the difficulties in modelling indirect vaccine effects (herd effect and serotype replacement), the absence of PHiD-CV- and PCV-13-specific efficacy data and a lack of comprehensive NTHi surveillance data. Additional limitations relate to the fact that the transmission dynamics of pneumococcal serotypes have not been modelled, nor has antibiotic resistance been accounted for in this paper.


CONCLUSIONS
This cost-effectiveness analysis suggests that, in Canada and the UK, PHiD-CV's potential to protect against NTHi infections could provide a greater impact on overall disease burden than the additional serotypes contained in PCV-13.
GlaxoSmithKline Biologicals, Wavre, Belgium. gk205@soton.ac.uk
Gerhart
G
Knerer
Afisi
A
Ismaila
David
D
Pearce
D000293:Adolescent; D000328:Adult; D000368:Aged; D001426:Bacterial Proteins / Q000191:economics* / Q000627:therapeutic use; D002170:Canada; D002352:Carrier Proteins / Q000191:economics* / Q000627:therapeutic use; D002648:Child; D002675:Child, Preschool; D003362:Cost-Benefit Analysis; D006801:Humans; D007072:Immunoglobulin D / Q000191:economics* / Q000627:therapeutic use; D008074:Lipoproteins / Q000191:economics* / Q000627:therapeutic use; D008390:Markov Chains; D008875:Middle Aged; D017063:Outcome Assessment, Health Care; D006113:United Kingdom; D018074:Vaccines, Conjugate / Q000191:economics* / Q000627:therapeutic use; D055815:Young Adult
D001426:Bacterial Proteins; D002352:Carrier Proteins; D007072:Immunoglobulin D; D008074:Lipoproteins; D018074:Vaccines, Conjugate; C067989:glpQ protein, Haemophilus influenzae